Axera Access Device

COMPANY Arstasis, Inc.
PHONE (877) 594-4545
WEB www.arstasis.com
KEY FEATURES

  • Rapid time to hemostasis
  • No patient implant
  • Superb safety profile
  • Excellent patient comfort

The Axera access device (Arstasis, Inc., Redwood City, CA) is a uniquefemoral artery access tool that quickly creates a longer and shallowerangle arteriotomy, resulting in significant tissue-on-tissue overlap through the artery. Upon sheath removal, arterial pressure decreases across this longer channel, providing an excellent environment for clot formation and rapid hemostasis, the company stated.

Using the Axera device requires only minimal compression to provide secure closure with no foreign body implants, eliminating the risk of implant infections and thomboembolic concerns. The procedure promotes rapid hemostasis resulting in excellent patient comfort with decreased bed rest and quicker ambulation.

NeverTouch 90-cm Procedure Kit,

COMPANY AngioDynamics.
PHONE (800) 772-6446
WEB www.venacure-evlt.com/ nevertouch
KEY FEATURES

  • 90-cm kit allows physicians to gain access above to ankle to treat varicose veins
  • Gold-tip fiber eliminates laser tip contact with the vein wall, minimizing perforations of the vein wall
  • Gold tip maximizes ultrasonic visibility
  • Lower-power density results in a homogeneous ablation with less focal charring of the vein wall

AngioDynamics (Queensbury, NY) recently launched the new 90-cm NeverTouch procedure kit featuring a longer TRE-Sheath introducer to gain access above the ankle for treating varicose veins that extend below the knee. The new kit complements existing kit lengths of 25, 45, and 65 cm and continues to build on the core benefits of the NeverTouch gold-tip laser fiber and VenaCure EVLT system. The primary innovation in the NeverTouch tip is a glass weld at the distal tip of a 600-μm fiber. The weld results in an effective fiber diameter of 905 μm and lowers the actual power density at the tip by 56% from that of a standard bare-tip 600-μm fiber. This provides a homogeneous ablation with less focal charring of the vein wall that is typically seen with bare-tip fibers. The gold jacketed tip also maximizes tip visibility under ultrasound and eliminates chances of inadvertent fiber tip contact with the vein wall, further improving safety and patient comfort, the company stated.

Mo.Ma Ultra Mono Balloon

COMPANY Medtronic
PHONE +41 52 260 0660
WEB www.invatec.com
KEY FEATURES

  • Proximal cerebral protection device with integrated guide catheter
  • Clinically proven, safe way to reduce embolism and periprocedural complications
  • Indicated for carotid lesions involving an occluded ECA
  • Patients are fully protected before the guidewire crosses the lesion
  • Occlusion-balloon in the CCA provides strong backup support

The original Mo.Ma Ultra (Medtronic Invatec, Frauenfeld, Switzerland) is a proximal cerebral protection device clinically proven to be a safe and effective way to reduce embolism and help prevent periprocedural complications in patients undergoing carotid stenting. The two occlusion balloons inflated in both the external carotid artery (ECA) and common carotid artery (CCA) temporarily suspend blood flow through the target treatment site. In its original configuration with tandem balloons, the Mo.Ma Ultra could be used in the majority of carotid anatomies; however, use in a patient with an occluded ECA was contraindicated, the company advised. The recently CE Marked Mo.Ma Ultra mono balloon expands Medtronic's portfolio, offering another option to treat lesions under complete proximal cerebral protection. This balloon may be used in treatment when there is an occluded ECA, which does not allow placement of an ECA balloon. Like the Mo.Ma Ultra double balloon, the Mo.Ma Ultra mono balloon fully protects patients before any device crosses the lesion because of flow suspension in the CCA. The occlusion- balloon provides strong backup support for successful lesion crossing and accurate stent deployment.